8-K: QuidelOrtho Reports Q3 2025 Results, $701M Goodwill Impairment

QuidelOrtho Corporation announced third quarter 2025 financial results, reporting total revenue of $700 million and a significant non-cash goodwill impairment charge of $701 million.

Summary

• Total revenue for the third quarter of 2025 was $700 million, a 4% decrease compared to $727 million in the prior year period.
• Non-respiratory revenue increased 5% as reported and 4% in constant currency to $588 million; excluding Donor Screening, this segment grew 6% in constant currency.
• Respiratory revenue was $112 million, primarily driven by a 63% decrease in COVID-19 revenue.
• GAAP net loss was $733 million, a significant increase from $20 million in the prior year period, largely due to a $701 million non-cash goodwill impairment charge.
• GAAP diluted loss per share was $10.78, compared to a loss of $0.30 in the prior year period.
• Adjusted diluted EPS was $0.80, a decrease from $0.85 in the prior year period.
• Adjusted EBITDA increased to $177 million from $171 million in the prior year period, with an adjusted EBITDA margin of 25%, an improvement of 180 basis points.
• The company successfully completed debt refinancing, which enhanced financial flexibility through improved terms and reduced amortization obligations.
• Full-year 2025 revenue and adjusted EBITDA guidance ranges were narrowed, and adjusted diluted EPS guidance was updated.

Sentiment

Score: 4

Explanation: While underlying non-respiratory business shows growth and adjusted EBITDA margin improved, the significant $701 million non-cash goodwill impairment charge leading to a substantial GAAP net loss and diluted loss per share is a major negative. The debt refinancing is positive for financial flexibility, but the overall GAAP performance is concerning.

Positives

• Non-respiratory revenue increased 5% as reported and 4% in constant currency to $588 million, demonstrating solid underlying growth.
• Excluding Donor Screening, non-respiratory revenue grew 6% in constant currency.
• Labs revenue grew 5% as reported and 4% in constant currency.
• GAAP operating expenses decreased by 6% and non-GAAP operating expenses decreased by 7%, driven by the company's cost-savings initiatives.
• Adjusted EBITDA increased to $177 million from $171 million in the prior year period.
• Adjusted EBITDA margin improved by 180 basis points to 25% compared to the prior year period.
• Successful completion of debt refinancing enhanced financial flexibility through improved terms and reduced amortization obligations.
• Accelerated innovation with the recent addition of high-sensitivity Troponin on the VITROS platform.

Negatives

• Total revenue decreased by 4% to $700 million compared to $727 million in the prior year period.
• GAAP net loss was $733 million, significantly higher than the $20 million loss in the prior year period.
• GAAP diluted loss per share was $10.78, a substantial increase from $0.30 in the prior year.
• A non-cash goodwill impairment charge of $701 million was recorded due to a decrease in the estimated fair value related to the decline in the company's stock price and market capitalization.
• Respiratory revenue declined to $112 million, primarily driven by a 63% decrease in COVID-19 revenue.
• Adjusted diluted EPS decreased to $0.80 from $0.85 in the prior year period.
• The company is in the process of winding down its U.S. Donor Screening portfolio, which saw a 47.3% decline in revenue.

Risks

• Fluctuations in demand for non-respiratory and respiratory products.
• Supply chain, production, logistics, distribution, and labor disruptions and challenges.
• Challenges and costs of integrating, restructuring, and achieving anticipated synergies from the business combination of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc or other acquisitions.
• Failure to exercise the option to acquire or complete the proposed acquisition of LEX Diagnostics on the anticipated timeline, or at all, including risks related to LEX Diagnostics' ability to secure FDA clearance and satisfy other customary closing conditions.
• Inability to realize anticipated benefits of acquisitions, debt refinancings, discontinuances of certain business operations (such as the discontinuance of development of the Savanna platform) or cost-savings and operational improvement initiatives.
• Delays in the development of or failures or delays in the receipt of approvals for new or enhanced products.
• Macroeconomic, geopolitical, market, business, competitive, and/or regulatory factors, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, and global trade relations.

Future Outlook

QuidelOrtho narrowed its full-year 2025 financial guidance, projecting total revenues between $2.68 billion and $2.74 billion, adjusted EBITDA between $585 million and $605 million (22% margin), and adjusted diluted EPS between $2.00 and $2.15. Foreign currency exchange is expected to be neutral for the full year 2025.

Management Comments

• "Our third quarter results reflect continued execution and meaningful progress against our strategic and financial priorities." Brian J. Blaser, President and Chief Executive Officer.
• "Through disciplined execution and focused investments in our highest-growth areas, we are expanding margins and accelerating innovation—most recently with the addition of high-sensitivity Troponin on our VITROS platform." Brian J. Blaser, President and Chief Executive Officer.
• "Backed by a broad portfolio, global reach, and operational focus, we believe we are well positioned to deliver sustainable growth and long-term value for our shareholders." Brian J. Blaser, President and Chief Executive Officer.

Industry Context

The results reflect a broader industry trend of declining COVID-19 related revenue, while the company demonstrates underlying strength in its core non-respiratory diagnostics segments, particularly Labs. The focus on expanding margins through cost-savings and accelerating innovation, such as the high-sensitivity Troponin on the VITROS platform, aligns with the competitive landscape in the in vitro diagnostics market where differentiation through technology and operational efficiency is key.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global industry benchmarks. Therefore, a direct comparison to industry standards cannot be made based solely on the provided information.

Legal Proceedings

• A "Legal accrual" of $9.4 million was included as an adjustment in the non-GAAP reconciliation for both the three and nine months ended September 28, 2025, indicating ongoing legal matters, though no specific proceedings are detailed.

Stakeholder Impact

• Shareholders are directly impacted by the $701 million goodwill impairment charge, leading to a significant GAAP net loss and diluted loss per share, potentially affecting stock price. They are positively impacted by improved adjusted EBITDA margin and debt refinancing.
• Employees are potentially impacted by cost-savings initiatives mentioned as a driver for decreased operating expenses.
• Customers benefit from accelerated innovation, such as the addition of high-sensitivity Troponin on the VITROS platform, and the company's commitment to advancing diagnostics.
• Creditors are positively impacted by the successful debt refinancing, which enhanced financial flexibility through improved terms and reduced amortization obligations.

Next Steps

• Hold an earnings conference call on November 5, 2025, at 2:00 p.m. PT / 5:00 p.m. ET to discuss financial results.
• Continue disciplined execution and focused investments in highest-growth areas.
• Accelerate innovation, as demonstrated by the recent addition of high-sensitivity Troponin on the VITROS platform.
• Work towards delivering sustainable growth and long-term value for shareholders.

Key Dates

Recommendation

The company's underlying non-respiratory business shows healthy growth, and management's cost-savings initiatives have led to improved adjusted EBITDA margins. The debt refinancing also strengthens financial flexibility. However, the substantial non-cash goodwill impairment charge of $701 million, resulting in a significant GAAP net loss, raises concerns about the company's valuation and market perception. While the core business appears stable, the impairment indicates a re-evaluation of asset values, which could weigh on investor sentiment. For existing investors, holding might be prudent to observe the impact of strategic initiatives and the market's reaction to the impairment. New investors might seek more clarity on the long-term implications of the impairment before committing capital.

Keywords

QuidelOrtho, QDEL, Financial Results, Q3 2025, Earnings, Goodwill Impairment, In Vitro Diagnostics, Diagnostic Solutions, Non-Respiratory Revenue, COVID-19 Revenue, Adjusted EBITDA, Debt Refinancing, Labs Revenue, Point of Care, Molecular Diagnostics, Immunohematology, Investor Relations